Perimeter Medical Imaging AI

Perimeter Medical Imaging AI is a pioneering medical technology company driven to transform cancer surgery with ultra-high resolution, real-time, advanced imaging tools that address unmet medical needs. Our goal is to improve patient outcomes and lower health care costs. Cancer is a global challenge, and we envision a world where patients no longer experience the costly emotional and physical trauma of being called back for a second surgery due to cancer left behind. A Toronto, Canada-based company established in 2013, with U.S. headquarters in Dallas, Texas, our proprietary technology allows surgeons to make more informed decisions during the surgical procedure. Until now, current technologies in the OR have not had the image resolution to identify microscopic features of excised tissues and shaved margins at the point-of-care. Our new OCT technology gives them real-time information vs. waiting several days for pathology reports. Perimeter S-Series OCT (Optical Coherence Tomography) is a groundbreaking medical imaging system that provides cross-sectional, real-time margin visualization of excised tissue specimens. It uses ultra-high-resolution OCT technology, developed out of MIT in 1991, an established imaging technology used in ophthalmology, cardiology and dermatology. Analogous to ultrasound images, OCT uses light waves instead of sound waves, and is now being applied in a novel way for intraoperative margin visualization. Cleared by the FDA, the Perimeter S-Series system provides cross-sectional images of tissues down to 2mm depth, with 10x higher image resolution than standard x-ray and ultrasound, and 100x greater than MRI. Perimeter is developing its proprietary, next-gen “ImgAssist” artificial intelligence technology under the ATLAS AI project, made possible, in part, by a $7.4 million grant awarded by the Cancer Prevention and Research Institute of Texas (CPRIT). The U.S. FDA granted Breakthrough Device Designation for Perimeter B-Series OCT coupled with ImgAssist AI. A randomized, multi-site, pivotal study is underway to evaluate this technology against the current standard of care and assess the impact on re-operation rates for patients undergoing breast conservation surgery.